Results 141 to 150 of about 6,478 (160)

Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants

Journal of Biological Chemistry, 2022
Roseann Ferré, Kimberly F Fennell, Claire Steppan   +2 more
exaly  

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS

Pharmaceuticals, 2022

exaly  

Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment.

Clinical Infectious Diseases, 2023
Antoine Chaillon, Tariq M Rana, Aaron F Carlin   +2 more
exaly  

Nirmatrelvir–ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis

Journal of Medical Virology, 2023
Zhaoyan Chen, Fangyuan Tian
exaly  

Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19.

Open Forum Infectious Diseases, 2022
Michael Usher, Nicolas Hoertel
exaly  

Paxlovid (nirmatrelvir/ritonavir).

WMJ : official publication of the State Medical Society of Wisconsin, 2022
Kristin, Busse, Abir T, El-Alfy
openaire   +1 more source

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance

EBioMedicine, 2023
Kelvin Kai-Wang To, Wan-Mui Chan, Rhoda Cheuk-Ying Leung   +2 more
exaly  

Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

International Journal of Antimicrobial Agents, 2023
Iker Falces-Romero, Francesco Marchesi, Oliver A. Cornely   +2 more
exaly  

Nirmatrelvir/ritonavir and pharmacovigilance data

The International Journal of Tuberculosis and Lung Disease
S, Lassan, M, Gocova, I, Solovic, T, Tesar, Z, Motesicka, M, Lassanova   +5 more
openaire   +2 more sources

Nirmatrelvir and ritonavir

Clinical Therapeutics
openaire   +2 more sources